Opinions Duncan Stewart
Isotechnnika IncISA.TODON'T BUYNov 18, 2008
Nothing fundamentally horrible about this company but it does have a small market cap, which is an out-of-favour sector. Small cap biotech sector is not a place to be.
$0.12
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
WEAK BUY
Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative.
Robert FloydOwned
biotechnologypharmaceutical
BUY
Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely.
Mike WeirOwned
biotechnologypharmaceutical
BUY
Thinks the stock should move up from this level. Have a good opportunity to bring their product to market. Should rally by the middle of 2004.
Mike WeirOwned
biotechnologypharmaceutical
BUY
An interesting little company. Good cash position. Strong management.
Robert FloydOwned
biotechnologypharmaceutical
BUY
